Sight Sciences director awarded 28,261 RSUs

Mazzacco Catherine reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Mazzacco Catherine reported acquisition or exercise transactions in this Form 4 filing.

Sight Sciences director Catherine Mazzacco received an equity grant as board compensation. She was awarded 28,261 restricted stock units (RSUs) of common stock on June 4, 2026 at no cash cost, equal to approximately $130,000 based on the closing price that day.

The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders, subject to her continued service on the board. After this grant, she holds 69,276 shares and RSUs directly, and 37,492 shares indirectly through an irrevocable trust where she is the beneficiary.

Insider Trade Summary

Grant/Award: 28,261 shares

Grant/Award 2 txns

Insider Mazzacco Catherine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	28,261	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 69,276 shares (Direct); Common Stock — 37,492 shares (Indirect, See footnote)

Footnotes (3)

1. F1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.
2. F2. Includes (i) 30,952 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported.
3. F3. These shares of Common Stock are held of record by the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 (the "Trust"), of which the Reporting Person is beneficiary.

Key Figures

RSU grant size: 28,261 RSUs Grant value: $130,000 Grant price per share: $0.0000 per share +4 more

7 metrics

RSU grant size 28,261 RSUs Granted June 4, 2026 as director compensation

Grant value $130,000 Approximate value based on June 4, 2026 closing price

Grant price per share $0.0000 per share RSUs granted with no cash exercise price

Vesting date June 4, 2027 or 2027 annual meeting RSUs vest on earlier of these dates with continued service

Direct holdings after grant 69,276 shares and RSUs Total direct common stock and RSUs following transaction

Indirect trust holdings 37,492 shares Common stock held by irrevocable trust for her benefit

Prior RSUs from 2023 10,063 RSUs RSUs granted June 8, 2023, still subject to vesting

Key Terms

restricted stock units ("RSUs"), Non-Employee Director Compensation Program, annual meeting of stockholders, irrevocable trust, +1 more

5 terms

restricted stock units ("RSUs") financial

"Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Non-Employee Director Compensation Program financial

"made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program"

annual meeting of stockholders financial

"The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders"

irrevocable trust financial

"held of record by the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

beneficiary financial

"the Trust, of which the Reporting Person is beneficiary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Catherine Mazzacco acquire in this Sight Sciences (SGHT) Form 4 filing?

Catherine Mazzacco received 28,261 restricted stock units (RSUs) of Sight Sciences common stock as board compensation. Each RSU represents one future share, giving her additional equity exposure without an immediate cash purchase or sale in the open market.

What is the dollar value of Catherine Mazzacco’s new RSU grant at Sight Sciences (SGHT)?

The RSU grant is valued at approximately $130,000, calculated using Sight Sciences’ closing stock price on June 4, 2026. This amount reflects standard non-employee director compensation rather than a discretionary stock purchase or sale by the director.

When do Catherine Mazzacco’s new Sight Sciences (SGHT) RSUs vest?

The 28,261 RSUs vest on the earlier of June 4, 2027 or the date of Sight Sciences’ 2027 annual meeting of stockholders. Vesting is conditioned on her continued service as a director on the company’s board through that vesting date.

How many Sight Sciences (SGHT) shares does Catherine Mazzacco hold after this transaction?

Following the RSU grant, she holds 69,276 shares and RSUs directly, combining existing stock and new awards. Separately, 37,492 common shares are held indirectly in an irrevocable trust where she is the beneficiary, as disclosed in the filing footnotes.

Is this Sight Sciences (SGHT) Form 4 a market buy or sell by Catherine Mazzacco?

No. The filing reports a grant of 28,261 RSUs at a price of $0.0000 per share under the non-employee director compensation program. This is a stock-based compensation award, not an open-market purchase or sale of Sight Sciences shares.

What is the role of the irrevocable trust in Catherine Mazzacco’s Sight Sciences (SGHT) holdings?

An irrevocable trust holds 37,492 shares of Sight Sciences common stock for which Catherine Mazzacco is the beneficiary. These shares are reported as indirect ownership, reflecting a separate legal holder, while still being associated with her economic interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazzacco Catherine

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		28,261(1)	A	$0.00	69,276(2)	D
Common Stock								37,492	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.

2. Includes (i) 30,952 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported.

3. These shares of Common Stock are held of record by the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 (the "Trust"), of which the Reporting Person is beneficiary.

	/s/Jeremy Hayden, Attorney-in-Fact for Catherine Mazzacco	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)